| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 7.1K | 0.3% |
| Total Income | 7.3K | 0.7% |
| Expenditure | 5.4K | 1.4% |
| PBT | 1.9K | 7.1% |
| Net Profit | 1.6K | 20.7% |
| OPM | 19.79% | 1.19pp |
| NPM | 21.71% | 3.68pp |
| EPS | 19.45 | 20.6% |
Cipla Limited Announces Q3 FY25 Results with Highest-Ever Quarterly Revenue at INR 7,000 Cr+ and EBITDA Margin at 28%+
28 Jan 2025 · 28 Jan 2025, 07:48 pm
Summary
Cipla Limited, a global pharmaceutical company, announced its unaudited consolidated financial results for the quarter ended December 31, 2024. The company reported a highest-ever quarterly revenue of INR 7,000 Cr+ and an EBITDA margin of 28%+. The One-India business grew at a healthy 10% YoY, North America delivered a revenue of $226 Mn, One Africa recorded a growth of 9% YoY in USD terms, and Emerging Markets and Europe posted a substantial revenue growth of 20% in USD terms. The company's R&D investments stood at INR 360 Cr or 5.1% of sales.
Key Highlights
- 1
Q3 FY25 results with highest-ever quarterly revenue at INR 7,000 Cr+ and EBITDA margin at 28%+
- 2
One-India business grew at a healthy 10% YoY
- 3
North America delivered a revenue of $226 Mn
- 4
One Africa recorded a growth of 9% YoY in USD terms
- 5
Emerging Markets and Europe posted a substantial revenue growth of 20% in USD terms
- 6
R&D investments stood at INR 360 Cr or 5.1% of sales
Management Comments
Umang Vohra
Pleased to share that we continue to make considerable progress across our focused markets. In Q3FY25, we delivered growth across all our various geographies, despite of a supply challenge in the U.S. We recorded a revenue growth of 8% over last year with a highest-ever EBITDA margin of 28.1%, driven by mix and other operational efficiencies.
Informational and educational content only. Not investment advice.